Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Murrell DF, et al. Among authors: kitajima y. J Am Acad Dermatol. 2008 Jun;58(6):1043-6. doi: 10.1016/j.jaad.2008.01.012. Epub 2008 Mar 14. J Am Acad Dermatol. 2008. PMID: 18339444 Free PMC article.
Grading criteria for disease severity by pemphigus disease area index.
Shimizu T, Takebayashi T, Sato Y, Niizeki H, Aoyama Y, Kitajima Y, Iwatsuki K, Hashimoto T, Yamagami J, Werth VP, Amagai M, Tanikawa A. Shimizu T, et al. Among authors: kitajima y. J Dermatol. 2014 Nov;41(11):969-73. doi: 10.1111/1346-8138.12649. J Dermatol. 2014. PMID: 25346300 Clinical Trial.
A randomized double-blind trial of intravenous immunoglobulin for pemphigus.
Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, Takigawa M, Seishima M, Tanaka T, Miyachi Y, Katayama I, Horiguchi Y, Miyagawa S, Furukawa F, Iwatsuki K, Hide M, Tokura Y, Furue M, Hashimoto T, Ihn H, Fujiwara S, Nishikawa T, Ogawa H, Kitajima Y, Hashimoto K; Pemphigus Study Group. Amagai M, et al. Among authors: kitajima y. J Am Acad Dermatol. 2009 Apr;60(4):595-603. doi: 10.1016/j.jaad.2008.09.052. J Am Acad Dermatol. 2009. PMID: 19293008 Clinical Trial.
Japanese guidelines for the management of pemphigus.
Committee for Guidelines for the Management of Pemphigus Disease; Amagai M, Tanikawa A, Shimizu T, Hashimoto T, Ikeda S, Kurosawa M, Niizeki H, Aoyama Y, Iwatsuki K, Kitajima Y. Committee for Guidelines for the Management of Pemphigus Disease, et al. Among authors: kitajima y. J Dermatol. 2014 Jun;41(6):471-86. doi: 10.1111/1346-8138.12486. J Dermatol. 2014. PMID: 24909210 Review.
From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases.
Ludwig RJ, Borradori L, Diaz LA, Hashimoto T, Hertl M, Ibrahim SM, Jonkman MF, Kitajima Y, Murrell DF, Schmidt E, Shimizu H, Stanley JR, Woodley DT, Zillikens D. Ludwig RJ, et al. Among authors: kitajima y. J Invest Dermatol. 2014 Sep;134(9):2298-2300. doi: 10.1038/jid.2014.171. J Invest Dermatol. 2014. PMID: 25120143 Free article. No abstract available.
Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"?
Amagai M, Ahmed AR, Kitajima Y, Bystryn JC, Milner Y, Gniadecki R, Hertl M, Pincelli C, Kurzen H, Fridkis-Hareli M, Aoyama Y, Frusić-Zlotkin M, Müller E, David M, Mimouni D, Vind-Kezunovic D, Michel B, Mahoney M, Grando S. Amagai M, et al. Among authors: kitajima y. Exp Dermatol. 2006 Oct;15(10):815-31. doi: 10.1111/j.1600-0625.2006.00499_1.x. Exp Dermatol. 2006. PMID: 16984264 Free article.
571 results